Latest LEO Pharma News & Updates

See the latest news and media coverage for LEO Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

LEO Pharma

Medical dermatology pharmaceutical company

leo-pharma.com

Headquarters: Ballerup, Denmark
Founded year: 1908
Company type: Private company
Number of employees: 1,000–6,000
Industry: Pharmaceuticals

Last updated Today

Latest news about LEO Pharma

In short: LEO Pharma reported 9% revenue growth for Q1 2026, acquired the Replay gene therapy platform, and advanced preparations for a potential IPO.

Company announcements

July 28 LEO Pharma

LEO Pharma receives Partners in Progress Award

The award recognizes its commitment to the EB community and its recent acquisition for gene therapy

July 9 LEO Pharma

LEO Pharma announces positive Phase 2 TRAPEDS-1 trial results

The trial evaluated tralokinumab in children aged 6-11 with moderate-to-severe atopic dermatitis, showing expected pharmacokinetics and long-term safety.

June 8 LEO Pharma

LEO Pharma's net-zero targets validated by SBTi

The company aims for net-zero by 2050 and near-term reductions by 2035, shifting from target-setting to implementation.

May 20 LEO Pharma

LEO Pharma begins phase 3 trial for Lichen Sclerosus

The first patient visit marks a milestone in the global study, part of ongoing innovation to address patient needs.

Media coverage

July 21 Jyllands-Posten

S-profile after revelation: Leo Pharma business raises »serious« questions

The Danish pharmaceutical company's growth in Russia raises, according to European spokesperson Kasper Roug (S), »serious ethical and societal questions«. The company owes an explanation, he believes. Leo Pharma...

July 9 Yahoo Finance

LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-S…

LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab ...

July 7 Børsen

Leo Pharma owner aims for second half of the year for IPO

Leo Pharma owner aims for second half of the year for IPOFor over 50 years ago, there were rumors of a sale of Leo Pharma to foreign companies. At that time, they decided...

July 3 EMJ

LEO Pharma acquires Replay gene therapy platform for $50m

LEO Pharma has acquired Replay, a herpes simplex virus (HSV) gene therapy platform, for $50m upfront, expanding the company’s presence in rare dermatology. The deal...

Never miss news about LEO Pharma

Track LEO Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.